Loading…
Orasure Technologies Inc
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
▼ -63.2% over 5Y.
today you would have $347.48▼ -65.3%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 17 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $2.42 | $3.61 | $8.20 | $4.82 | $8.69 | $10.59 | $8.03 | $11.68 | $18.86 | $8.78 | $6.44 | $10.14 | $6.29 | $7.18 | $9.11 | $5.75 | $5.08 | |
Seven formulas applied to what the company reported. None of them predicts a price — each answers what the stock would be worth if its assumption held. The assumption is printed next to every number, because it is the assumption that produces the result.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| LYELLyell Immunopharma, Inc. | $11.15 | — | 1.1x | — | -93.28% | $273.23M |
| ANIKAnika Therapeutics, Inc. | $20.38 | — | 2.0x | — | -2.19% | $272.68M |
| TRDAEntrada Therapeutics, Inc. | $7.00 | — | 0.9x | — | -54.09% | $272.56M |
| ACIUAC Immune SA | $2.73 |
OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, sells, and distributes diagnostic products and specimen collection devices in the United States, Europe, Africa, and internationally. It offers OraQuick Rapid HIV test, OraQuick HIV self-test, OraQuick HIV self-test(international), OraQuick HCV rapid antibody test and self-test, Syphilis health check rapid diagnostic test, OraQuick Ebola rapid antigen test, InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, SickleSCAN test, and OraSure oral fluid collection device for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. The company also provides genomic products under the Oragene and ORAcollect brands for collecting genetic material from human saliva; Colli-Pee collection devices for the volumetric collection of urine samples; and HEMAcollect protein blood collection device. In addition, it provides microbiome products, such as OMNIgene GUT for self-collecting microbial DNA from feces or stool samples for gut microbiome profiling; OMNIgene GUT DNA and RNA collection devices; OMNIgene SALIVA DNA and RNA collection devices; and OMNIgene GUT Dx collection device for collection of human fecal samples and the stabilization of DNA from the bacterial community. Further, it offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests. Additionally, it develops a molecular self-test for chlamydia trachomatis and neisseria gonorrhoeae. It sells its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, commercial and industrial entities, disease risk management, diagnostics, pharmaceutical, biotech, and companion animal, markets. The company was founded in 1987 and is headquartered in Bethlehem, Pennsylvania.
Company description provided by Yahoo Finance.
| P/E |
| 35.4x |
| — |
| — |
| 11.4x |
| — |
| — |
| 48.1x |
| 29.7x |
| 35.4x |
| 37.0x |
| 25.1x |
| 46.0x |
| — |
| — |
| — |
| — |
| — |
| — |
| P/S | 3.5x | 1.5x | 1.5x | 1.5x | 0.9x | 2.7x | 4.4x | 3.2x | 4.0x | 6.9x | 3.9x | 3.0x | 5.4x | 3.5x | 4.5x | 5.4x | 3.5x | — |
| P/B | 2.2x | 0.5x | 0.7x | 1.4x | 1.0x | 1.7x | 1.9x | 1.6x | 2.5x | 4.5x | 2.7x | 2.2x | 3.6x | 2.2x | 2.3x | 4.4x | 2.6x | — |
| EPS | -$0.94 | -$0.26 | $0.72 | -$0.24 | -$0.32 | $0.22 | $0.27 | $0.33 | $0.51 | $0.35 | $0.14 | -$0.08 | -$0.20 | -$0.29 | -$0.19 | -$0.08 | -$0.17 |
| Profit margin | -4.66% | -59.76% | -10.49% | 13.23% | -4.42% | -9.84% | -8.69% | 10.77% | 11.22% | 18.52% | 15.38% | 6.82% | -4.33% | -11.31% | -17.21% | -10.80% | -4.66% | -10.14% |
| ROE | -3.74% | -20.17% | -4.75% | 12.46% | -4.70% | -6.04% | -3.74% | 5.42% | 7.20% | 11.99% | 10.61% | 5.12% | -2.91% | -6.94% | -8.87% | -8.82% | -3.40% | -7.53% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
Dividend growing 0.0% a year against a 9.0% required return, taken from the stock’s beta. The only method anchored on what the company pays rather than what it reports.
Not the average of the seven numbers above. Four of the seven start from the same earnings per share — Graham, Lynch, sector multiples and its own history — so averaging all seven would let one input count four times and drown out the others. Instead each family produces one number, and the fair price is the average of the families that answered. A family with two working formulas contributes their average, not two votes.
1 methods answered, across 1 families.
Every formula reads the same reported statements and they can be wrong together. The margin is room for that.
+347.8% from the average.
These are models, not forecasts, and not investment advice. Change one assumption and the number changes with it — that is a property of valuation, not a defect of this page.
| — |
| 6.3x |
| — |
| -78.53% |
| $271.44M |
| LCTXLineage Cell Therapeutics, Inc. | $1.11 | — | 4.6x | — | -60.06% | $280.73M |
| PYXSPyxis Oncology, Inc. | $3.23 | — | 17.9x | — | -179.10% | $269.41M |